Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Cardiology

Treatment Options and Medication Risks

At a Glance

For hypertensive heart disease, sustained blood pressure control is the key treatment goal because it reduces strain and may reverse heart muscle thickening. Medicines can help but require personalized monitoring for kidney problems, abnormal potassium, dehydration, and allergic reactions.

Treating hypertensive heart disease (HHD) is a long-term commitment to changing the environment in which your heart works. The goal of treatment is twofold: to lower the pressure your heart must push against and, where possible, to encourage reverse remodeling—the process of the heart muscle thinning back toward its normal, healthy state [1][2]. No medication should be started or stopped just to pursue reverse remodeling without a doctor’s guidance.

The Foundation of Treatment

Because HHD is caused by chronic pressure, the foundation of care is blood pressure control. Doctors typically use several classes of medication, often in combination, to achieve this [3]. The preferred class depends on your kidney disease, albuminuria, diabetes, and other factors.

ACE Inhibitors and ARBs

These medications block hormones that cause blood vessels to tighten. ACE inhibitors (like lisinopril) and Angiotensin Receptor Blockers or ARBs (like losartan) are common first-line options for patients with heart remodeling [3][4].

  • Reverse Remodeling: Both classes are highly effective at helping the heart muscle shrink back toward normal size [3].
  • Risks and Monitoring: Both can cause hyperkalemia (dangerously high potassium levels) and may affect your kidney function, especially when you first start them [5][6]. Your doctor will recheck your blood shortly after starting them. ACE inhibitors specifically can cause a persistent, dry cough in some patients and a rare but serious allergic reaction called angioedema (swelling of the lips, tongue, or throat) [7]. If you experience swelling of the lips, tongue, or throat, call 911 or go to the emergency room immediately.
  • Important Safety Rule: You should never take an ACE inhibitor and an ARB at the same time [8]. Research has shown that combining them does not provide extra heart protection but significantly increases the risk of kidney failure and dangerously high potassium [6][9]. If prescribed both, promptly verify the regimen with your prescriber.

Diuretics (“Water Pills”)

Diuretics help your kidneys remove extra salt and water from your body, which reduces the total volume of blood your heart has to pump [10].

  • Thiazide-like Diuretics: Often used for blood pressure control [11].
  • Loop Diuretics: Primarily used if you have symptoms of fluid buildup, like swollen ankles or shortness of breath [12].
  • Risks: These medications can cause volume depletion (dehydration) and electrolyte imbalances, such as low sodium or low potassium [11][13]. They can also increase uric acid levels, which may trigger a gout attack in some patients [13].

Calcium Channel Blockers (CCBs)

These drugs (like amlodipine) prevent calcium from entering the muscle cells of your heart and blood vessels, allowing them to relax [14].

  • Side Effects: A common side effect is pedal edema (swelling of the ankles and feet), which is caused by the blood vessels in the legs relaxing and leaking fluid into the surrounding tissue [14].

New Frontiers: SGLT2 Inhibitors

Originally developed for diabetes, SGLT2 inhibitors (like empagliflozin or dapagliflozin) have become a breakthrough treatment for patients who have clinically diagnosed, symptomatic HFpEF (Heart Failure with Preserved Ejection Fraction) [15]. (Note: Having a normal EF or LVH alone is not an indication for these drugs).

  • Benefit: These medications significantly reduce the risk of being hospitalized for heart failure and improve quality of life [15][16]. They work in several ways, including helping the kidneys clear excess sugar and salt and potentially reducing scarring within the heart muscle [17][18].
  • Risks: The most common side effects are genital yeast infections, dehydration (especially with diuretics), and a slight risk of symptomatic low blood pressure [19]. Rarely, they can cause a serious condition called euglycemic ketoacidosis. Ask your doctor for sick-day instructions for when to hold this medication (e.g., severe vomiting or fasting for surgery).

The Goal: Reversing the Damage

The most powerful tool for “fixing” the heart is consistent, sustained blood pressure control. While some medications may have a slight edge in promoting reverse remodeling, the most important factor is reaching your target blood pressure [2][20]. When the pressure is lowered, the heart no longer needs the extra muscle bulk (LVH), and it can begin to return to a more efficient shape and size [2].

Because these medications affect your internal chemistry, your doctor will likely order regular blood tests to monitor your creatinine (a measure of kidney function) and potassium levels [5][21]. Always report new symptoms—like a cough, dizziness, or swelling—promptly to your care team.

Common questions in this guide

What is the main treatment goal for hypertensive heart disease?
The main goal is sustained blood pressure control, which reduces the force the heart must pump against and may allow thickened heart muscle to move toward a healthier size. The best medication plan depends on factors such as kidney disease, protein in the urine, diabetes, and other health conditions.
Is it safe to take an ACE inhibitor and an ARB together?
ACE inhibitors and ARBs should not be taken together. Combining them does not add heart protection and can increase the risk of kidney failure and dangerously high potassium; if both appear on your medication list, promptly contact your prescriber to verify what you should take.
Which blood tests are needed when starting these heart medicines?
After starting an ACE inhibitor or ARB, your clinician will commonly recheck creatinine, a blood marker of kidney function, and potassium soon afterward. Depending on your treatment, blood tests may also monitor sodium, other electrolytes, hydration, and uric acid.
When might an SGLT2 inhibitor be used for hypertensive heart disease?
SGLT2 inhibitors such as empagliflozin or dapagliflozin are used for people with clinically diagnosed, symptomatic HFpEF, meaning heart failure in which the pumping percentage is preserved. A normal ejection fraction or heart muscle thickening alone is not enough reason to use one. These medicines may lower the risk of hospitalization for heart failure, but your clinician should review dehydration, infection, low blood pressure, and sick-day precautions.
What side effects can diuretics and calcium channel blockers cause?
Diuretics may cause dehydration, low sodium or potassium, and increased uric acid that can trigger gout. Calcium channel blockers such as amlodipine commonly cause swelling in the ankles or feet. Report dizziness, muscle cramps, or new swelling to your care team.
What should I do if my lips or tongue swell after taking an ACE inhibitor?
Swelling of the lips, tongue, or throat may be angioedema, a rare but serious reaction to an ACE inhibitor. Call 911 or go to the emergency room immediately, particularly if you have trouble breathing or swallowing.
Can an ACE inhibitor cause a persistent dry cough?
Yes, ACE inhibitors can cause a persistent dry cough in some people. Tell your prescriber about the cough rather than stopping the medicine on your own, because they can decide whether a different treatment is appropriate.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my goal blood pressure, and how often will we monitor my potassium and kidney function on these new medications?
  2. 2.Am I currently taking an ACE inhibitor and an ARB together? (If so, why is this combination being used despite the risks?)
  3. 3.Which of my current medications is most likely to help my heart muscle thin back toward a normal size (reverse remodeling)?
  4. 4.Is my 'ejection fraction' still in the normal range, and should we add an SGLT2 inhibitor to reduce my risk of being hospitalized for heart failure?
  5. 5.What should I do if I develop a persistent dry cough or notice any swelling of my lips or tongue?
  6. 6.Are there specific symptoms, like dizziness or muscle cramps, that would suggest my diuretic dose is too high or my electrolytes are out of balance?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    The Evolution from Hypertension to Heart Failure.

    Sorrentino MJ

    Heart failure clinics 2019; (15(4)):447-453 doi:10.1016/j.hfc.2019.06.005.

    PMID: 31472880
  2. 2

    Is Left Ventricular Hypertrophy a Valid Therapeutic Target?

    Brooks JE, Soliman EZ, Upadhya B

    Current hypertension reports 2019; (21(6)):47 doi:10.1007/s11906-019-0952-9.

    PMID: 31111289
  3. 3

    Hypertension and heart failure with preserved ejection fraction: position paper by the European Society of Hypertension.

    Kasiakogias A, Rosei EA, Camafort M, et al.

    Journal of hypertension 2021; (39(8)):1522-1545 doi:10.1097/HJH.0000000000002910.

    PMID: 34102660
  4. 4

    Should ACE inhibitors and ARBs be used in combination in children?

    Stotter BR, Ferguson MA

    Pediatric nephrology (Berlin, Germany) 2019; (34(9)):1521-1532 doi:10.1007/s00467-018-4046-8.

    PMID: 30112656
  5. 5

    Optimizing renin-angiotensin-aldosterone inhibition in advanced chronic kidney disease: balancing benefits and risks.

    Spencer S, Bhandari S

    Current opinion in nephrology and hypertension 2025; (34(6)):469-476 doi:10.1097/MNH.0000000000001076.

    PMID: 40207744
  6. 6

    Efficacy and safety of dual vs single renin-angiotensin-aldosterone system blockade in chronic kidney disease: An updated meta-analysis of randomized controlled trials.

    Zhao M, Qu H, Wang R, et al.

    Medicine 2021; (100(35)):e26544 doi:10.1097/MD.0000000000026544.

    PMID: 34477114
  7. 7

    Angiotensin-Converting Enzyme Inhibitors in Hypertension: To Use or Not to Use?

    Messerli FH, Bangalore S, Bavishi C, Rimoldi SF

    Journal of the American College of Cardiology 2018; (71(13)):1474-1482 doi:10.1016/j.jacc.2018.01.058.

    PMID: 29598869
  8. 8

    Cardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses.

    Catalá-López F, Macías Saint-Gerons D, González-Bermejo D, et al.

    PLoS medicine 2016; (13(3)):e1001971 doi:10.1371/journal.pmed.1001971.

    PMID: 26954482
  9. 9

    A Real-World Analysis of Post-Marketing Surveillance Data Assessing the Incidence of Hyperkalemia or Acute Kidney Injury in Patients on Angiotensin-Converting Enzyme Inhibitors Versus Angiotensin-Receptor Blockers.

    Wang Y, Ren Q, Luo H, et al.

    Reviews in cardiovascular medicine 2023; (24(4)):107 doi:10.31083/j.rcm2404107.

    PMID: 39076277
  10. 10

    [Antihypertensive drug therapy : Where do we stand?].

    Middeke M

    Der Internist 2015; (56(3)):230-9 doi:10.1007/s00108-014-3570-2.

    PMID: 25707372
  11. 11

    Therapeutic roles of thiazides and loop diuretics in blood pressure control and renal protection against chronic kidney disease.

    Jo W, Koh ES, Chung S

    Clinical hypertension 2023; (29(1)):14 doi:10.1186/s40885-023-00238-5.

    PMID: 37183259
  12. 12

    Treatment of heart failure with preserved ejection fraction with SGLT2 inhibitors: new therapy standard?

    Schneider CA, Pfister R

    Herz 2022; (47(5)):395-400 doi:10.1007/s00059-022-05134-6.

    PMID: 36018379
  13. 13

    Antihypertensive therapy in diabetes mellitus: efficacy, safety, and metabolic impacts in type 1 and type 2 diabetes.

    Joshi P, Rick G, Mesineni S, et al.

    Cardiovascular diabetology. Endocrinology reports 2026; (12(1)):4 doi:10.1186/s40842-025-00268-y.

    PMID: 41703653
  14. 14

    Cutaneous effects of antihypertensive drugs.

    Baccino D, Merlo G, Cozzani E, et al.

    Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia 2020; (155(2)):202-211 doi:10.23736/S0392-0488.19.06360-0.

    PMID: 31195782
  15. 15

    Effect of Sodium-Glucose Cotransporter 2 Inhibitors for Heart Failure With Preserved Ejection Fraction: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.

    Zhou H, Peng W, Li F, et al.

    Frontiers in cardiovascular medicine 2022; (9()):875327 doi:10.3389/fcvm.2022.875327.

    PMID: 35600478
  16. 16

    [Diagnosis and treatment of heart failure with preserved ejection fraction].

    Soltani S, Bauersachs J

    Herz 2025; (50(5)):395-404 doi:10.1007/s00059-025-05327-9.

    PMID: 40853593
  17. 17

    Clinical Evidence and Proposed Mechanisms of Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction: A Class Effect?

    Deschaine B, Verma S, Rayatzadeh H

    Cardiac failure review 2022; (8()):e23 doi:10.15420/cfr.2022.11.

    PMID: 35846984
  18. 18

    [The effect of sodium-glucose cotransporter type 2 inhibitors on left ventricular diastolic function: current status and prospects].

    Borisova EV, Barsukov AV, Glebova SA, Airapetyan AV

    Kardiologiia 2024; (64(7)):64-71 doi:10.18087/cardio.2024.7.n2545.

    PMID: 39102575
  19. 19

    Efficacy of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors in Heart Failure With Preserved Ejection Fraction: A Systematic Review.

    Santos Guzmán MV, Rivera D, Reyna Guerrero IM, et al.

    Cureus 2025; (17(5)):e84129 doi:10.7759/cureus.84129.

    PMID: 40519421
  20. 20

    Effects of sacubitril/valsartan on hypertensive heart disease: the REVERSE-LVH randomized phase 2 trial.

    Lee V, Dalakoti M, Zheng Q, et al.

    Nature communications 2025; (16(1)):6981 doi:10.1038/s41467-025-62203-0.

    PMID: 40739095
  21. 21

    Concurrent analogous organ damage in the brain, eyes, and kidneys in malignant hypertension: reversible encephalopathy, serous retinal detachment, and proteinuria.

    Mishima E, Funayama Y, Suzuki T, et al.

    Hypertension research : official journal of the Japanese Society of Hypertension 2021; (44(1)):88-97 doi:10.1038/s41440-020-0521-2.

    PMID: 32719463

This page explains hypertensive heart disease treatments and medication risks for educational purposes and does not constitute medical advice. Do not start, stop, or combine medicines without guidance from your prescriber.

Get notified when new evidence is published on hypertensive heart disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.